Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4324
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOzen, M.E.-
dc.contributor.authorYumru, M.-
dc.contributor.authorSavas, H.-
dc.contributor.authorCansel, N.-
dc.contributor.authorHerken, H.-
dc.date.accessioned2019-08-16T11:33:25Z-
dc.date.available2019-08-16T11:33:25Z-
dc.date.issued2007-
dc.identifier.issn1562-2975-
dc.identifier.urihttps://hdl.handle.net/11499/4324-
dc.identifier.urihttps://doi.org/10.1080/15622970600774202-
dc.description.abstractNeuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone. Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause. The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone. This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.en_US
dc.language.isoenen_US
dc.relation.ispartofWorld Journal of Biological Psychiatryen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeuroleptic malignant syndromeen_US
dc.subjectSchizophreniaen_US
dc.subjectTreatmenten_US
dc.subjectZiprasidoneen_US
dc.subjectbiperidenen_US
dc.subjectdiazepamen_US
dc.subjectolanzapineen_US
dc.subjectziprasidoneen_US
dc.subjectadulten_US
dc.subjectarticleen_US
dc.subjectcase reporten_US
dc.subjectclinical featureen_US
dc.subjectdisease durationen_US
dc.subjectdrug urine levelen_US
dc.subjecthumanen_US
dc.subjectmaleen_US
dc.subjectneuroleptic malignant syndromeen_US
dc.subjectneurologic examinationen_US
dc.subjectrectum temperatureen_US
dc.subjectschizophreniaen_US
dc.subjecttreatment durationen_US
dc.subjecttreatment outcomeen_US
dc.subjectAdulten_US
dc.subjectAntipsychotic Agentsen_US
dc.subjectBiperidenen_US
dc.subjectDiagnosis, Differentialen_US
dc.subjectDiazepamen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectHumansen_US
dc.subjectInfusions, Intravenousen_US
dc.subjectMaleen_US
dc.subjectNeuroleptic Malignant Syndromeen_US
dc.subjectNeurologic Examinationen_US
dc.subjectParkinsonian Disordersen_US
dc.subjectPiperazinesen_US
dc.subjectThiazolesen_US
dc.titleNeuroleptic malignant syndrome induced by ziprasidone on the second day of treatmenten_US
dc.typeArticleen_US
dc.identifier.volume8en_US
dc.identifier.issue1en_US
dc.identifier.startpage42
dc.identifier.startpage42en_US
dc.identifier.endpage44en_US
dc.identifier.doi10.1080/15622970600774202-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid17366349en_US
dc.identifier.scopus2-s2.0-33847168475en_US
dc.identifier.wosWOS:000244774600007en_US
dc.identifier.scopusqualityQ1-
dc.ownerPamukkale University-
item.languageiso639-1en-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.dept08.04. Business Administration-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

16
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

10
checked on Sep 30, 2024

Page view(s)

52
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.